F/M Emr Life Sciences in ETFLFSCETF
13F holders, Q2 2025 (June 30)3holders −1
1new positions
2sold out
$24.62avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding F/M Emr Life Sciences in ETF (LFSC) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were Emerald Mutual Fund Advisers Trust ($49.2M), Hunter Associates Investment Management LLC ($1.0M) and UBS Group AG ($21K).
- Company
- F/M Emr Life Sciences in ETF
- Filed as
- RBB FD INC (Q2 2025)
- CUSIP
- 74933W221
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $49.2M |
| Exits | 2 | $325K |
All 13F filers, Q1 2025 → Q2 2025: 2,001,981 shares bought and 14,467 shares sold, net +1,987,514 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Emerald Mutual Fund Advisers Trust | 2.99% | New | 1,997,035 | $49.2M |
| Hunter Associates Investment Management LLC | 0.15% | Add +11.2% | 40,740 | $1.0M |
| UBS Group AG | 0.00% | Add +10562.5% | 853 | $21K |
"% of holder's portfolio" is LFSC's weight in each manager's 13F, not the share of F/M Emr Life Sciences in ETF the manager owns.